EICHOR
● Not Yet Recruiting
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants
Condition: Ebola-Bundibugyo Virus Disease (Ebola-BDBV) · Sponsor: ModernaTX, Inc.
About this study
The main objective of this trial is to evaluate the safety and reactogenicity of mRNA-1469
This description comes directly from the study's public registry record.
Talk to the study team
Moderna WeCareTeam · 1-866-663-3762 · WeCareClinicalTrials@modernatx.com
Always discuss trial participation with your own doctor first.
Locations (3)
| Canadian Center for Vaccinology | Halifax, Nova Scotia, Canada | — |
| Colchester Research Group | Truro, Nova Scotia, Canada | — |
| Centricity Research Toronto LMC Multispecialty | Toronto, Ontario, Canada | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07737717